Senicapoc

Senicapoc
Names
	Preferred IUPAC name 2,2-Bis(4-fluorophenyl)-2-phenylacetamide
Identifiers
CAS Number	289656-45-7 ;
3D model (JSmol)	Interactive image;
ChemSpider	187516 ;
IUPHAR/BPS	2331;
KEGG	D06640 ;
PubChem CID	216327;
UNII	TS6G201A6Q ;
CompTox Dashboard (EPA)	DTXSID60276906 ;
	InChI InChI=1S/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24) Key: SCTZUZTYRMOMKT-UHFFFAOYSA-N ; InChI=1/C20H15F2NO/c21-17-10-6-15(7-11-17)20(19(23)24,14-4-2-1-3-5-14)16-8-12-18(22)13-9-16/h1-13H,(H2,23,24) Key: SCTZUZTYRMOMKT-UHFFFAOYAR;
	SMILES C1=CC=C(C=C1)C(C2=CC=C(C=C2)F)(C3=CC=C(C=C3)F)C(=O)N;
Properties
Chemical formula	C20H15F2NO
Molar mass	323.34 g/mol
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

Senicapoc (ICA-17043) is a Gardos channel blocker.^[1]^[2]

It has been proposed for use in sickle cell anemia.^[3] Gardos channel blockers may work in the treatment of sickle cell anemia by blocking the efflux of potassium and water from red blood cells, thereby preventing the dehydration of red blood cells and stopping the polymerization of HbS.

The Gardos channel has been identified as KCNN4.^[4]

The "ICA" is for Icagen, which is developing the drug.^[5]

References

^ Ataga KI, Smith WR, De Castro LM, et al. (April 2008). "Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia". Blood. 111 (8): 3991–7. doi:10.1182/blood-2007-08-110098. PMID 18192510.
^ McNaughton-Smith GA, Burns JF, Stocker JW, et al. (February 2008). "Novel inhibitors of the Gardos channel for the treatment of sickle cell disease". J. Med. Chem. 51 (4): 976–82. doi:10.1021/jm070663s. PMID 18232633.
^ Ataga KI; Stocker J (February 2009). "Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia". Expert Opin Investig Drugs. 18 (2): 231–9. doi:10.1517/13543780802708011. PMID 19236269. S2CID 73061898.
^ Hoffman JF; Joiner W; Nehrke K; Potapova O; Foye K; Wickrema A (June 2003). "The hSK4 (KCNN4) isoform is the Ca2+-activated K+ channel (Gardos channel) in human red blood cells". Proc. Natl. Acad. Sci. U.S.A. 100 (12): 7366–71. Bibcode:2003PNAS..100.7366H. doi:10.1073/pnas.1232342100. PMC 165881. PMID 12773623.
^ "Icagen - Press Release". Retrieved 2008-12-22.

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

[pmid18192510-1] Ataga KI, Smith WR, De Castro LM, et al. (April 2008). "Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia". Blood. 111 (8): 3991–7. doi:10.1182/blood-2007-08-110098. PMID 18192510.

[pmid18232633-2] McNaughton-Smith GA, Burns JF, Stocker JW, et al. (February 2008). "Novel inhibitors of the Gardos channel for the treatment of sickle cell disease". J. Med. Chem. 51 (4): 976–82. doi:10.1021/jm070663s. PMID 18232633.

[pmid19236269-3] Ataga KI; Stocker J (February 2009). "Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia". Expert Opin Investig Drugs. 18 (2): 231–9. doi:10.1517/13543780802708011. PMID 19236269. S2CID 73061898.

[pmid12773623-4] Hoffman JF; Joiner W; Nehrke K; Potapova O; Foye K; Wickrema A (June 2003). "The hSK4 (KCNN4) isoform is the Ca2+-activated K+ channel (Gardos channel) in human red blood cells". Proc. Natl. Acad. Sci. U.S.A. 100 (12): 7366–71. Bibcode:2003PNAS..100.7366H. doi:10.1073/pnas.1232342100. PMC 165881. PMID 12773623.

[urlIcagen_-_Press_Release-5] "Icagen - Press Release". Retrieved 2008-12-22.

[1]

[2]

[3]

[4]

[5]